CRISPR Therapeutics presents Phase 1 zugo-cel data in refractory systemic sclerosis at ACR Convergence 2026

By Public Technologies
  • CRISPR Therapeutics flagged Phase 1 clinical data for its CD19-targeting allogeneic CAR-T candidate zugo-cel in refractory systemic sclerosis.
  • Results have not been presented yet, with a poster scheduled for ACR Convergence 2026 on Nov. 8, 2026.
  • The readout is positioned to inform early views on safety and potential efficacy in autoimmune disease.
  • Zugo-cel remains in Phase 1 testing across autoimmune indications, supporting a broader push beyond hemoglobinopathies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610021015PRIMZONEFULLFEED9838713) on October 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk